Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NV-07a: NVGN began a Phase I of NV-07a in 15 nickel sensitive patients and 15 mantoux positive patients.

Novogen Ltd. (NVGN; ASX:NRT), Sydney,

Read the full 56 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE